Filing Flows

Filing Flows › Bio-Rad Laboratories (BIO) › Who owns the stock

Who owns Bio-Rad Laboratories (BIO) stock

385 funds reported Bio-Rad Laboratories (BIO) shares in their latest 13F filings, worth $6.9B in all. The largest holder is First Eagle Investment Management, LLC ($1.5B). Last quarter 154 funds added to their stakes and 186 cut them.

Largest holders of BIO (13F)Largest holders of BIO (13F)First Eagle Investment Management…$1.5BVanguard Group$538MBlackRock$499MDimensional Fund Advisors LP$277MVanguard Capital Management LLC$243MAriel Investments, LLC$240MVanguard Portfolio Management LLC$240MEarnest Partners LLC$171MState Street$168MBank of America$144M

Largest holders (13F)

FundSharesValueChangeQuarter
First Eagle Investment Management, LLC5,212,438$1.5Bincrease2026-06-30
Vanguard Group1,774,263$538Mdecrease2025-12-31
BlackRock1,698,929$499Mincrease2026-06-30
Dimensional Fund Advisors LP944,548$277Mdecrease2026-06-30
Vanguard Capital Management LLC826,972$243Mdecrease2026-06-30
Ariel Investments, LLC816,751$240Mincrease2026-06-30
Vanguard Portfolio Management LLC816,198$240Mdecrease2026-06-30
Earnest Partners LLC580,752$171Mdecrease2026-06-30
State Street571,762$168Mincrease2026-06-30
Bank of America490,412$144Mincrease2026-06-30
Capital World Investors462,457$136Mincrease2026-06-30
Capital Research Global Investors443,483$130Mincrease2026-06-30
UBS AM, a distinct business unit of UBS Asset Management Americas LLC418,884$123Mdecrease2026-06-30
Barclays322,152$122Mincrease2026-09-30
First Pacific Advisors, LP401,861$118Mdecrease2026-06-30

Bio-Rad Laboratories' latest quarter

Bio-Rad Laboratories, Q3 2026: revenue $656M (+0.5% year over year), operating margin -7.6%, net earnings $459M, operating cash flow $96.4M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most BIO stock?

By the latest 13F filings: First Eagle Investment Management, LLC ($1.5B); Vanguard Group ($538M); BlackRock ($499M); Dimensional Fund Advisors LP ($277M); Vanguard Capital Management LLC ($243M).

What is the short interest in BIO?

1,097,562 shares were sold short at the 2026-10-15 settlement, -7.2% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.